The health and well-being of our donors is our top priority. Our Follow-up and Donor–Patient Contact teams (FU/DPC) are responsible for the post-donation care and follow-up for all our DKMS donors, as well as for any communication between the donor and patient.
Our Cell Therapy Services team is the point of contact for any institution seeking HLA matched donor derived starting material to manufacture Advanced Therapy Medicinal Products (ATMP) for clinical trials or for approved drugs.